PubMed

PET/CT scans in ovarian cancer: prognostic versus predictive utility?

Markman M.

Minerva Med. 2009 Oct;100(5):415-20.PMID: 19910893 [PubMed - in process]Related articles

Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, Vahdat LT, Obel J, Vogelzang N, Markman M, Sweetenham JW, Pfister D, Kris MG, Schuchter LM, Sawaya R, Raghavan D, Ganz PA, Kramer B.

J Clin Oncol. 2009 Dec 10;27(35):6052-69. Epub 2009 Nov 9. No abstract available. PMID: 19901123 [PubMed - in process]Related articles

Phase I clinical trials in 56 patients with thyroid cancer: the M. D. Anderson Cancer Center experience.

Tsimberidou AM, Vaklavas C, Wen S, Hong D, Wheler J, Ng C, Naing A, Tse S, Busaidy N, Markman M, Sherman SI, Kurzrock R.

J Clin Endocrinol Metab. 2009 Nov;94(11):4423-32. Epub 2009 Oct 9.PMID: 19820016 [PubMed - in process]Related articles

Ovarian cancer.

Hennessy BT, Coleman RL, Markman M.

Lancet. 2009 Oct 17;374(9698):1371-82. Epub 2009 Sep 28.PMID: 19793610 [PubMed - indexed for MEDLINE]Related articles

Chemotherapy: Topotecan or treosulfan--that is the question.

Markman M.

Nat Rev Clin Oncol. 2009 Oct;6(10):559-60. No abstract available. PMID: 19786996 [PubMed - in process]Related articles

"Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma" Safra T, et al (Gynecol Oncol 2009; 114:215-218).

Markman M.

Gynecol Oncol. 2009 Dec;115(3):514; author reply 514-5. Epub 2009 Sep 18. No abstract available. PMID: 19766296 [PubMed - indexed for MEDLINE]Related articles

Comparative effectiveness research: a proposal for funding in ovarian cancer.

Markman M.

Gynecol Oncol. 2009 Nov;115(2):182-3. Epub 2009 Aug 20. No abstract available. PMID: 19695689 [PubMed - indexed for MEDLINE]Related articles

Antiangiogenic drugs in ovarian cancer.

Markman M.

Expert Opin Pharmacother. 2009 Oct;10(14):2269-77. Review.PMID: 19671017 [PubMed - indexed for MEDLINE]Related articles

Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.

Cox JD, Giralt SA, Veazie ML, Ajani JA, Bruner JM, Chan KW, Hittelman WN, Hunt KK, Iyer RB, Karp DD, Kuban DA, Lippman SM, Raad II, Rodriguez-Bigas MA, Zwelling LA, Markman M.

Oncology. 2009;77(2):75-81. Epub 2009 Jul 1.PMID: 19571599 [PubMed - indexed for MEDLINE]Related articles

Presentation of chemotherapy options for cervix cancer on cancer-related Internet sites.

Markman M.

J Womens Health (Larchmt). 2009 Jun;18(6):827-9.PMID: 19514823 [PubMed - indexed for MEDLINE]Related articles

The impact of PET-CT in suspected recurrent ovarian cancer: a prospective multi-centre study as part of the Australian PET Data Collection Project.

Markman M.

Gynecol Oncol. 2009 Sep;114(3):536; author reply 536-7. Epub 2009 May 31. No abstract available. PMID: 19482342 [PubMed - indexed for MEDLINE]Related articles

Single-agent trabectedin as second-line therapy of persistent or recurrent endometrial cancer: results of a multicenter phase II study.

McMeekin DS, Lisyanskaya A, Crispens M, Oza AM, Braly P, Doering D, Bayever E, Michiels B, Markman M.

Gynecol Oncol. 2009 Aug;114(2):288-92. Epub 2009 May 23.PMID: 19476988 [PubMed - indexed for MEDLINE]Related articles

Southwest Oncology Group Trial S9912: intraperitoneal cisplatin and paclitaxel plus intravenous paclitaxel and pegylated liposomal doxorubicin as primary chemotherapy of small-volume residual stage III ovarian cancer.

Smith HO, Moon J, Wilczynski SP, Tiersten AD, Hannigan EV, Robinson WR, Rivkin SE, Anderson GL, Liu PY, Markman M.

Gynecol Oncol. 2009 Aug;114(2):206-9. Epub 2009 May 23.PMID: 19464730 [PubMed - indexed for MEDLINE]Related articles

Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial.

Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D.

Gynecol Oncol. 2009 Aug;114(2):195-8. Epub 2009 May 17.PMID: 19447479 [PubMed - indexed for MEDLINE]Related articles

Intraperitoneal chemotherapy in the management of ovarian cancer: focus on carboplatin.

Markman M.

Ther Clin Risk Manag. 2009 Feb;5(1):161-8. Epub 2009 Mar 26.PMID: 19436618 [PubMed - in process]Related articlesFree article

Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma.

Micha JP, Goldstein BH, Rettenmaier MA, Brown JV 3rd, John CR, Markman M.

Int J Gynecol Cancer. 2009 Feb;19(2):239-41.PMID: 19396000 [PubMed - indexed for MEDLINE]Related articles

Survival after second-line intraperitoneal therapy for the treatment of epithelial ovarian cancer: the Gynecologic Oncology Group experience.

Markman M, Brady M, Hutson A, Berek JS.

Int J Gynecol Cancer. 2009 Feb;19(2):223-9.PMID: 19395997 [PubMed - indexed for MEDLINE]Related articles

An update on the use of intraperitoneal chemotherapy in the management of ovarian cancer.

Markman M.

Cancer J. 2009 Mar-Apr;15(2):105-9. Review.PMID: 19390303 [PubMed - indexed for MEDLINE]Related articles

Hypersensitivity reactions: an increasingly recognized toxicity of platinum agents.

Markman M.

Oncology. 2009;76(4):229-30. Epub 2009 Feb 25. No abstract available. PMID: 19246946 [PubMed - indexed for MEDLINE]Related articles

Prevalence of pulmonary hypertension in patients with schistosomal liver fibrosis.

Ferreira RC, Domingues AL, Bandeira AP, Markman Filho B, Albuqerque Filho ES, Correiade de Araújo AC, Batista LJ, Markman M, Campelo AR.

Ann Trop Med Parasitol. 2009 Mar;103(2):129-43.PMID: 19208297 [PubMed - in process]Related articles

CA-125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study.

Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, Rose PG, Spriggs D, Armstrong DK.

Cancer. 2009 Apr 1;115(7):1395-403. Review.PMID: 19195045 [PubMed - indexed for MEDLINE]Related articles

Hyperthermic intraperitoneal chemotherapy in the management of ovarian cancer: A critical need for an evidence-based evaluation.

Markman M.

Gynecol Oncol. 2009 Apr;113(1):4-5. Epub 2009 Jan 26. No abstract available. PMID: 19176238 [PubMed - indexed for MEDLINE]Related articles

Therapeutic intent in the conduct of phase I antineoplastic drug trials.

Markman M.

Oncology. 2009;76(3):149-50. Epub 2009 Jan 23. No abstract available. PMID: 19169045 [PubMed - indexed for MEDLINE]Related articles

The myth of measurable disease in ovarian cancer: revisited.

Markman M.

Cancer Invest. 2009 Jan;27(1):11-2. Review.PMID: 19160094 [PubMed - indexed for MEDLINE]Related articles

The prognostic value of pretreatment CA 125 in patients with advanced ovarian carcinoma: a Gynecologic Oncology Group study.

Zorn KK, Tian C, McGuire WP, Hoskins WJ, Markman M, Muggia FM, Rose PG, Ozols RF, Spriggs D, Armstrong DK.

Cancer. 2009 Mar 1;115(5):1028-35.PMID: 19156927 [PubMed - indexed for MEDLINE]Related articles

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous A6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer.

Markman M.

Gynecol Oncol. 2009 Jul;114(1):136-7; authore reply 137. Epub 2009 Jan 12. No abstract available. PMID: 19138792 [PubMed - indexed for MEDLINE]Related articles

Phase II evaluation of neoadjuvant chemotherapy and debulking followed by intraperitoneal chemotherapy in women with stage III and IV epithelial ovarian, fallopian tube or primary peritoneal cancer: Southwest Oncology Group Study S0009.

Tiersten AD, Liu PY, Smith HO, Wilczynski SP, Robinson WR 3rd, Markman M, Alberts DS.

Gynecol Oncol. 2009 Mar;112(3):444-9. Epub 2009 Jan 12.PMID: 19138791 [PubMed - indexed for MEDLINE]Related articles

Clinical cancer advances 2008: major research advances in cancer treatment, prevention, and screening--a report from the American Society of Clinical Oncology.

Winer E, Gralow J, Diller L, Karlan B, Loehrer P, Pierce L, Demetri G, Ganz P, Kramer B, Kris M, Markman M, Mayer R, Pfister D, Raghavan D, Ramsey S, Reaman G, Sandler H, Sawaya R, Schuchter L, Sweetenham J, Vahdat L, Schilsky RL; American Society of Clinical Oncology.

J Clin Oncol. 2009 Feb 10;27(5):812-26. Epub 2008 Dec 22. Erratum in: J Clin Oncol. 2009 Jun 20;27(18):3070-1. PMID: 19103723 [PubMed - indexed for MEDLINE]Related articles

Progression-free survival versus overall survival as the primary end point in anticancer drug trials: increasingly relevant impact of therapy following progression.

Markman M.

Curr Oncol Rep. 2009 Jan;11(1):1-2. No abstract available. PMID: 19080733 [PubMed - indexed for MEDLINE]Related articles

Predictive value of neoadjuvant chemotherapy for the clinical utility of subsequently performed major cancer surgery.

Markman M.

Curr Oncol Rep. 2008 Nov;10(6):447-8. No abstract available. PMID: 18928657 [PubMed - indexed for MEDLINE]Related articles

Lack of reliability of CA125 response criteria with anti-VEGF molecularly targeted therapy.

Markman M.

Cancer. 2008 Nov 15;113(10):2832-3; author reply 2833-4. No abstract available. PMID: 18846540 [PubMed - indexed for MEDLINE]Related articlesFree article

Diagnostic evaluations of unproven clinical utility in oncology: a real-life example of their harmful consequences.

Markman M.

Curr Oncol Rep. 2008 Jul;10(4):271-2. No abstract available. PMID: 18778550 [PubMed - indexed for MEDLINE]Related articles

Benefits of religious beliefs for cancer patients: a response to Dawkins and Hitchens.

Markman M.

Curr Oncol Rep. 2008 May;10(3):185-7. No abstract available. PMID: 18765147 [PubMed - indexed for MEDLINE]Related articles

Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies.

Markman M.

Trends Pharmacol Sci. 2008 Oct;29(10):515-9. Epub 2008 Aug 28. Review.PMID: 18760845 [PubMed - indexed for MEDLINE]Related articles

Risk of toxicity versus risk of death: a complex equation in the management of highly curable malignancies.

Markman M.

Curr Oncol Rep. 2008 Sep;10(5):359-60. No abstract available. PMID: 18706261 [PubMed - indexed for MEDLINE]Related articles

The remarkable "paclitaxel story": how many chapters remain to be written?

Markman M.

Gynecol Oncol. 2008 Oct;111(1):7-8. Epub 2008 Aug 5. No abstract available. PMID: 18682311 [PubMed - indexed for MEDLINE]Related articles

Society of gynecologic oncologists position paper: breast cancer care.

SGO Breast Cancer Task Force, Orr J Jr, Kelley J 3rd, Dizon D, Escobar P, Fleming E, Gemignani M, Hetzel D, Hoskins W, Kieback D, Kilgore L, LaPolla J, Lewin S, Lucci J, Markman M, Pothuri B, Powell CB, Tejada-Berges T.

Gynecol Oncol. 2008 Jul;110(1):7-12. No abstract available. PMID: 18589209 [PubMed - indexed for MEDLINE]Related articles

Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: a strategy to improve the quality of gynecologic cancer clinical research.

Markman M.

Gynecol Oncol. 2008 Sep;110(3):275-7. Epub 2008 Jun 30. No abstract available. PMID: 18586312 [PubMed - indexed for MEDLINE]Related articles

Second-line therapy for ovarian cancer.

Markman M.

Clin Adv Hematol Oncol. 2008 Jun;6(6):421-2. No abstract available. PMID: 18567987 [PubMed - indexed for MEDLINE]Related articles

The promise and perils of 'targeted therapy' of advanced ovarian cancer.

Markman M.

Oncology. 2008;74(1-2):1-6. Epub 2008 Jun 9. Review.PMID: 18536523 [PubMed - indexed for MEDLINE]Related articles

Assigning a cause for a particular outcome in oncology: a serious note of caution.

Markman M.

Cancer. 2008 Aug 15;113(4):668-70. No abstract available. PMID: 18506763 [PubMed - indexed for MEDLINE]Related articlesFree article

Comorbidity as a focus of clinical cancer trials: an important unmet need.

Markman M.

Oncology. 2007;73(5-6):279-80. Epub 2008 May 13. No abstract available. PMID: 18477852 [PubMed - indexed for MEDLINE]Related articles

Intraperitoneal chemotherapy as primary treatment of advanced ovarian cancer: efficacy, toxicity, and future directions.

Markman M.

Rev Recent Clin Trials. 2007 Sep;2(3):169-73. Review.PMID: 18474002 [PubMed - indexed for MEDLINE]Related articles

Pharmaceutical management of ovarian cancer : current status.

Markman M.

Drugs. 2008;68(6):771-89. Review.PMID: 18416585 [PubMed - indexed for MEDLINE]Related articles

Development of an effective breast and cervix cancer screening strategy in Mumbai: an impressive effort.

Markman M.

Oncology. 2007;73(3-4):143-4. Epub 2008 Apr 11. No abstract available. PMID: 18408400 [PubMed - indexed for MEDLINE]Related articles

Maintenance chemotherapy in advanced ovarian cancer: the US experience.

Markman M.

Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:40-3. Review.PMID: 18336399 [PubMed - indexed for MEDLINE]Related articles

What is the optimal approach to the administration of intraperitoneal chemotherapy in ovarian cancer?

Markman M.

Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:36-9. Review.PMID: 18336398 [PubMed - indexed for MEDLINE]Related articles

Strategies to examine new compounds for intraperitoneal use in ovarian cancer.

Markman M.

Int J Gynecol Cancer. 2008 Mar-Apr;18 Suppl 1:33-5. Review.PMID: 18336397 [PubMed - indexed for MEDLINE]Related articles

Combination versus sequential chemotherapy administration: is it time for a reevaluation of the issue?

Markman M.

Curr Oncol Rep. 2008 Mar;10(2):93-4. No abstract available. PMID: 18377820 [PubMed - indexed for MEDLINE]Related articles

The increasingly complex world of cancer patient advocacy organizations.

Markman M.

Curr Oncol Rep. 2008 Jan;10(1):1-2. No abstract available. PMID: 18366953 [PubMed - indexed for MEDLINE]Related articles